IntrinsicIntrinsic
← All summaries

BioXcel Therapeutics, Inc.

BTAI
Financials & Chart →

Business Summary

BioXcel Therapeutics, Inc. is a biopharmaceutical company that leverages artificial intelligence (AI) to develop transformative medicines in neuroscience, with a wholly owned subsidiary, OnkosXcel Therapeutics, focused on immuno-oncology. The company's proprietary AI platform is designed to reduce therapeutic development costs and accelerate timelines by identifying new therapeutic indications for existing approved drugs or clinically evaluated product candidates, utilizing big data and machine learning algorithms . This approach aims to re-innovate drugs by understanding relationships between neuropsychiatric symptoms, brain circuits, drug targets, and existing drugs, potentially leading to novel uses or combinations of drugs .

The core business model revolves around drug re-innovation, focusing on identifying new uses for launched drugs or shelved clinical candidates. This strategy is exemplified by the successful development and commercialization of IGALMI® (dexmedetomidine) sublingual film, as well as the advancement of BXCL501 for other potential indications . The company generates revenue primarily through product sales of IGALMI® and aims to expand its commercialization efforts for additional indications and product candidates.

The most advanced neuroscience candidate is BXCL501, an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine, developed for the treatment of agitation associated with psychiatric and neurological disorders . On April 6, 2022, the FDA approved IGALMI® (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, available in 120 and 180 micrograms ("mcg") doses . The SERENITY At-Home Pivotal Phase 3 trial, evaluating BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting, met its primary objective on August 27, 2025, with data forming the basis of an sNDA submission for label expansion . Positive topline exploratory efficacy data from this trial, announced on September 10, 2025, demonstrated continued effects and consistent benefit with repeat dosing . A correlation study announced on October 10, 2025, showed a strong correlation between clinician and patient/caregiver assessments, supporting the use of mCGI-S for efficacy assessment in the outpatient setting .

The TRANQUILITY program evaluates BXCL501 for agitation associated with Alzheimer’s dementia (AAD) in outpatient or in-care facilities. The TRANQUILITY II Phase 3 trial met its primary efficacy endpoint with the 60 mcg dose, showing a statistically significant 7.5 point reduction from baseline in PEC total score at 2 hours versus 5.4 with placebo (p=0.0112) . The 60 mcg dose also met the first key secondary endpoint at 1 hour (p=0.0185) . However, an investigator misconduct issue at one site, enrolling approximately 40% of patients, was investigated, with the FDA designating "Voluntary Action Indicated" for the site, which the company believes supports data reliability .

The most advanced immuno-oncology asset, BXCL701, is an investigational oral innate immune activator from OnkosXcel Therapeutics, a potential therapy for aggressive prostate cancer, pancreatic cancer, and other solid and liquid tumors . BXCL701 demonstrated a 25% composite response rate in a Phase 2a clinical trial for small cell neuroendocrine carcinoma (SCNC) phenotype metastatic castration-resistant prostate cancer (mCRPC) . On February 12, 2024, BXCL701 received Fast Track designation from the FDA for investigation in combination with a checkpoint inhibitor for metastatic SCNC . Development of BXCL701 programs has been deprioritized, except for specific ongoing efforts .

For the year ended December 31, 2025, the company reported net revenues from IGALMI® product sales of $0.6 million, a decrease from $2.3 million for the year ended December 31, 2024 . The net loss for the year ended December 31, 2025, was $69.9 million, compared to $59.6 million for the year ended December 31, 2024 . As of December 31, 2025, the company had cash, cash equivalents, and restricted cash of $28.8 million . Total principal indebtedness outstanding under the Credit Agreement was $112.2 million as of December 31, 2025 .

The company undertook a Clinical Reprioritization in 2024 and 2025 to preserve cash and prioritize core clinical programs. This included reducing its workforce by approximately 15% on May 8, 2024, with related restructuring costs paid in the second quarter of 2024 . An additional 28% workforce reduction occurred on September 17, 2024, with $475 of related costs paid in the first quarter of 2025 and $128 paid in the second quarter of 2025 . Restructuring costs for the years ended December 31, 2025 and 2024 were $0.2 million and $2.4 million, respectively . The investment in and utilization of the proprietary AI platform was also reduced in the third quarter of 2025 until additional funding becomes available .

Business Outlook

Management believes that the company's cash, cash equivalents, and restricted cash of $28.8 million as of December 31, 2025, combined with $0.5 million of gross proceeds from sales pursuant to the Company ATM Program after December 31, 2025, and $8.0 million of gross proceeds from its registered direct offering in March 2026, will allow the company to fund its operations and meet liquidity requirements into the second quarter of 2026 . However, there is no assurance that the cash runway will be extended .

The company submitted a supplemental New Drug Application (sNDA) to the FDA on January 14, 2026, for IGALMI® for the acute treatment of agitation associated with schizophrenia and bipolar disorders in the at-home setting . This sNDA aims to expand IGALMI®'s label to include the broader at-home patient population . The company received positive pre-sNDA meeting responses from the FDA on August 18, 2025, and believes the planned sNDA regulatory package will be sufficient . The SERENITY At-Home Pivotal Phase 3 trial, evaluating the safety of BXCL501 in the at-home setting, met its primary objective on August 27, 2025, and positive topline exploratory efficacy data was announced on September 10, 2025, demonstrating continued effects and consistent benefit with repeat dosing . A correlation study announced on October 14, 2025, showed a strong correlation between clinician and patient/caregiver rated outcomes, supporting the use of mCGI-S to assess efficacy in the outpatient setting .

For the TRANQUILITY program, the company is planning to generate additional Phase 3 efficacy and safety data for BXCL501 in a variety of relevant care-facility settings and across severity of dementia, through a planned TRANQUILITY In-Care Phase 3 trial . The proposed protocol for this trial, designed to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for agitation associated with Alzheimer’s dementia, was submitted to the FDA on September 5, 2024, and feedback was received on November 12, 2024 . The company also plans to discuss the details of the requirement for long-term safety data at a future meeting with the FDA . Patient screening and enrollment for an outpatient study evaluating BXCL501 in alcohol use disorder with comorbid PTSD is expected to begin in the first half of 2026 . Similarly, patient screening and enrollment for a study of BXCL501 for treating Acute Stress Disorder (ASD) is expected to begin in the first half of 2026 .

The company continues to supply IGALMI® through existing distribution channels and is maintaining its market presence with minimal commercial resources while seeking potential commercial partners . Commercialization efforts are designed to build the foundation for additional potential follow-on indications . If IGALMI® is approved outside the U.S., the company would consider launching the product through collaborations with third parties . An Interim Chief Commercial Officer was appointed on January 12, 2026, to support the potential launch of IGALMI® in the at-home setting .

The company's Credit Agreement contains a minimum liquidity covenant, which, as of September 30, 2025, required maintaining at least $15.0 million of unrestricted cash and cash equivalents, subsequently reduced to $12.5 million in the Ninth Amendment . Quarterly amortization payments equal to 5.0% of the principal amount outstanding under the Credit Agreement, along with applicable prepayment fees, are required to begin on March 31, 2026 . Additionally, under the Ninth Amendment, following receipt of aggregated gross proceeds from Capital Raise Activities, the company has agreed to make a prepayment of loans equal to 50% of such gross cash proceeds, with certain exceptions for the first $2.5 million and once the aggregate prepaid amount reaches $2.5 million .

Risk Factors

The company has identified conditions that raise substantial doubt about its ability to continue as a going concern, with $28.8 million in cash, cash equivalents, and restricted cash as of December 31, 2025, and insufficient cash to support operations and debt obligations for at least one year . The Credit Agreement requires audited annual financial statements without a "going concern" qualification, which was waived for the year ended December 31, 2025, through the Ninth Amendment . This amendment also reduced the minimum liquidity covenant to $12.5 million and requires a one-time prepayment of $2.5 million by March 31, 2026 , along with potential amendment fees or warrants and a 50% prepayment of gross cash proceeds from Capital Raise Activities, with certain exceptions . The company faces risks from its limited operating history and significant operating losses, with a net loss of $69.9 million for the year ended December 31, 2025 and a stockholders’ deficit of approximately $95.5 million . Substantial additional funding is required, and failure to raise capital could force delays or elimination of product development or commercialization efforts . Developments in the TRANQUILITY II Phase 3 trial, including investigator misconduct at a site enrolling approximately 40% of patients, may impact the timing and prospects for regulatory approval of BXCL501 for agitation associated with Alzheimer’s disease . The FDA has indicated a need for additional efficacy data, including repeat efficacy data, and long-term safety data for up to one year to support an sNDA submission for this indication . The company's estimated total addressable market for its products is subject to inherent challenges and uncertainties, based on internal and third-party estimates that may be inaccurate, potentially harming revenue and profitability . The discovery and development of product candidates based on the EvolverAI and the company's AI platform is novel and unproven, with no guarantee of commercial value . The company is also exposed to risks from employee misconduct, including noncompliance with regulatory standards and insider trading . Unfavorable global political or economic events, such as the current military conflict between Russia and Ukraine and the war between Israel and Hamas, and related sanctions or tariffs, could adversely affect business, financial condition, or results of operations .

Management Priorities

Management's message to shareholders emphasizes a strategic clinical reprioritization to focus on high-potential agitation-market opportunities, including a shift in commercial strategy for IGALMI® in the institutional setting, reduced in-hospital commercialization expenses, and a suspension of non-core programs . The primary strategic priority is to prioritize the development of BXCL501 for use in the at-home setting for the acute treatment of agitation in schizophrenia, bipolar disorders, and in patients with mild to moderate dementia due to probable Alzheimer’s disease . Management believes that the company's existing cash, cash equivalents, and restricted cash of $28.8 million as of December 31, 2025, combined with $0.5 million from ATM sales and $8.0 million from a March 2026 registered direct offering, will fund operations into the second quarter of 2026 . The company submitted an sNDA on January 14, 2026, for IGALMI® for at-home use in schizophrenia and bipolar disorders, following positive pre-sNDA meeting responses from the FDA .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Our Novel Drug Re-Innovation Approach
  3. [3] Item 1, Business — Our Novel Drug Re-Innovation Approach
  4. [4] Item 1, Business — Our Business
  5. [5] Item 1, Business — Our Business
  6. [6] Item 1, Business — Our Business
  7. [7] Item 1, Business — Our Business
  8. [8] Item 1, Business — Our Business
  9. [9] Item 1, Business — TRANQUILITY Program: Acute Agitation Associated with Dementia due to Probable Alzheimer’s Disease (AAD)
  10. [10] Item 1, Business — TRANQUILITY Program: Acute Agitation Associated with Dementia due to Probable Alzheimer’s Disease (AAD)
  11. [11] Item 1, Business — TRANQUILITY Program: Acute Agitation Associated with Dementia due to Probable Alzheimer’s Disease (AAD)
  12. [12] Item 1, Business — Our Business
  13. [13] Item 1, Business — Immuno-Oncology
  14. [14] Item 1, Business — Immuno-Oncology
  15. [15] Item 1, Business — Our Business
  16. [16] Item 1, Business — IGALMI ® Commercial Strategy
  17. [17] Item 1A, Risk Factors — We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.
  18. [18] Item 1A, Risk Factors — We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.
  19. [19] Item 1A, Risk Factors — We have significant indebtedness and other contractual obligations that could impair our liquidity, restrict our ability to do business and thereby harm our business, results of operations and financial condition. We may not have sufficient cash flow from operations to satisfy our obligations under the Credit Agreement.
  20. [20] Item 1, Business — 2024 Clinical Reprioritization
  21. [21] Item 1, Business — 2024 Clinical Reprioritization
  22. [22] Item 1, Business — Human Capital
  23. [23] Item 1, Business — 2024 Clinical Reprioritization
  24. [24] Item 1A, Risk Factors — We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.
  25. [25] Item 1A, Risk Factors — We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.
  26. [26] Item 1, Business — Our Neuroscience Clinical Programs and Investigator-Sponsored Trials
  27. [27] Item 1A, Risk Factors — We have limited clinical data supporting potential safety or efficacy of BXCL501 for use in the at-home setting in the acute treatment of agitation in patients with dementia due to probable Alzheimer’s disease and patients with schizophrenia and bipolar patients.
  28. [28] Item 1, Business — SERENITY Program: Acute Treatment of Agitation Associated with Bipolar Disorders I and II or Schizophrenia
  29. [29] Item 1, Business — SERENITY Program: Acute Treatment of Agitation Associated with Bipolar Disorders I and II or Schizophrenia
  30. [30] Item 1, Business — SERENITY Program: Acute Treatment of Agitation Associated with Bipolar Disorders I and II or Schizophrenia
  31. [31] Item 1, Business — TRANQUILITY Program: Acute Agitation Associated with Dementia due to Probable Alzheimer’s Disease (AAD)
  32. [32] Item 1, Business — TRANQUILITY Program: Acute Agitation Associated with Dementia due to Probable Alzheimer’s Disease (AAD)
  33. [33] Item 1, Business — TRANQUILITY Program: Acute Agitation Associated with Dementia due to Probable Alzheimer’s Disease (AAD)
  34. [34] Item 1, Business — Alcohol Use Disorder with Comorbid Post-traumatic Stress Disorder Program
  35. [35] Item 1, Business — Acute Stress Disorder (ASD) Program
  36. [36] Item 1, Business — IGALMI ® Commercialization Strategy
  37. [37] Item 1, Business — IGALMI ® Commercialization Strategy
  38. [38] Item 1, Business — IGALMI ® Commercialization Strategy
  39. [39] Item 1, Business — IGALMI ® Commercialization Strategy
  40. [40] Item 1A, Risk Factors — We have significant indebtedness and other contractual obligations that could impair our liquidity, restrict our ability to do business and thereby harm our business, results of operations and financial condition. We may not have sufficient cash flow from operations to satisfy our obligations under the Credit Agreement.
  41. [41] Item 1A, Risk Factors — We have significant indebtedness and other contractual obligations that could impair our liquidity, restrict our ability to do business and thereby harm our business, results of operations and financial condition. We may not have sufficient cash flow from operations to satisfy our obligations under the Credit Agreement.
  42. [42] Item 1A, Risk Factors — We have significant indebtedness and other contractual obligations that could impair our liquidity, restrict our ability to do business and thereby harm our business, results of operations and financial condition. We may not have sufficient cash flow from operations to satisfy our obligations under the Credit Agreement.
  43. [43] Item 1A, Risk Factors — We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.
  44. [44] Item 1A, Risk Factors — We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.
  45. [45] Item 1A, Risk Factors — We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.
  46. [46] Item 1A, Risk Factors — We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.
  47. [47] Item 1A, Risk Factors — We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.
  48. [48] Item 1A, Risk Factors — We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.
  49. [49] Item 1A, Risk Factors — We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.
  50. [50] Item 1A, Risk Factors — We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.
  51. [51] Item 1A, Risk Factors — We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.
  52. [52] Item 1A, Risk Factors — Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer’s disease.
  53. [53] Item 1A, Risk Factors — Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer’s disease.
  54. [54] Item 1A, Risk Factors — Our estimated number of episodes of agitation and our corresponding estimated total addressable market are subject to inherent challenges and uncertainties. If we have overestimated the number of episodes or the size of our total addressable market for our current and potential future products or product candidates, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be harmed.
  55. [55] Item 1A, Risk Factors — The discovery and development of product candidates based on EvolverAI, BioXcel LLC’s proprietary pharmaceutical discovery and development engine, and our AI platform is novel and unproven, and we do not know whether we will be able to develop any products of commercial value.
  56. [56] Item 1A, Risk Factors — Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.
  57. [57] Item 1A, Risk Factors — Unfavorable global political or economic events and conditions could adversely affect our business, financial condition or results of operations.
  58. [58] Item 1A, Risk Factors — Our Clinical Reprioritization and other workforce reductions may not achieve our intended outcome.
  59. [59] Item 1A, Risk Factors — Our Clinical Reprioritization and other workforce reductions may not achieve our intended outcome.
  60. [60] Item 1A, Risk Factors — We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.
  61. [61] Item 1A, Risk Factors — We have limited clinical data supporting potential safety or efficacy of BXCL501 for use in the at-home setting in the acute treatment of agitation in patients with dementia due to probable Alzheimer’s disease and patients with schizophrenia and bipolar patients.

Analysis on 5/20/2026